I kliniske undersøgelser, hvor valsartan blev sammenlignet med en ACE- hæmmer, var incidensen af tør hoste signifikant (p < 0, 05) mindre hos patienter i behandling med valsartan end hos patienter i behandling med en ACE- hæmmer (2, 6% versus 7, 9%, henholdsvis).
In clinical trials where valsartan was compared with an ACE inhibitor, the incidence of dry cough was significantly (p < 0.05) lower in patients treated with valsartan than in those treated with an ACE inhibitor (2.6% versus 7.9%, respectively).